Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P K Leichner

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Oncology (Williston Park, N.Y.)|May 1, 1989
Current status of radioimmunoglobulins in the treatment of human malignancyS E Order, A M Sleeper, G B Stillwagon, et al.
Cancer Treatment Reports|July 1, 1983
Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liverP K Leichner, J L Klein, S S Siegelman, et al.
International Journal of Radiation Oncology, Biology, Physics|February 1, 1986
90Yttrium antiferritin--a new therapeutic radiolabeled antibodyS E Order, J L Klein, P K Leichner, et al.
Radiology|July 1, 1986
Skeletal metastases from hepatoma: frequency, distribution, and radiographic featuresJ E Kuhlman, E K Fishman, P K Leichner, et al.
Nuclear Medicine and Biology|July 1, 1993
Preclinical evaluation of intravenously administered 111In- and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogsS M Quadri, Y Shao, J E Blum, et al.
Medical Physics|March 1, 1993
An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapyP K Leichner, K F Koral, R J Jaszczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1987
Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancerJ V Sitzmann, S E Order, J L Klein, et al.
International Journal of Radiation Oncology, Biology, Physics|August 1, 1985
A model system that predicts effective half-life for radiolabeled antibody therapyJ L Klein, M N Ling, P K Leichner, et al.
Cancer Drug Delivery|January 1, 1984
Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancersP K Leichner, J L Klein, E K Fishman, et al.
American Journal of Clinical Oncology|October 1, 1985
Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapyD S Ettinger, P K Leichner, S S Siegelman, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Oncology (Williston Park, N.Y.)|May 1, 1989
Current status of radioimmunoglobulins in the treatment of human malignancyS E Order, A M Sleeper, G B Stillwagon, et al.
Cancer Treatment Reports|July 1, 1983
Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liverP K Leichner, J L Klein, S S Siegelman, et al.
International Journal of Radiation Oncology, Biology, Physics|February 1, 1986
90Yttrium antiferritin--a new therapeutic radiolabeled antibodyS E Order, J L Klein, P K Leichner, et al.
Radiology|July 1, 1986
Skeletal metastases from hepatoma: frequency, distribution, and radiographic featuresJ E Kuhlman, E K Fishman, P K Leichner, et al.
Nuclear Medicine and Biology|July 1, 1993
Preclinical evaluation of intravenously administered 111In- and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogsS M Quadri, Y Shao, J E Blum, et al.
Medical Physics|March 1, 1993
An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapyP K Leichner, K F Koral, R J Jaszczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1987
Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancerJ V Sitzmann, S E Order, J L Klein, et al.
International Journal of Radiation Oncology, Biology, Physics|August 1, 1985
A model system that predicts effective half-life for radiolabeled antibody therapyJ L Klein, M N Ling, P K Leichner, et al.
Cancer Drug Delivery|January 1, 1984
Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancersP K Leichner, J L Klein, E K Fishman, et al.
American Journal of Clinical Oncology|October 1, 1985
Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapyD S Ettinger, P K Leichner, S S Siegelman, et al.
Pageof 6